This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. On Friday, Sept. 2, 2022, federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they're set to give its maker, Amylyx, a rare second chance to make its case publicly. (Amylyx via AP)
Featured Photo Galleries
Trump Transition: Here are the people Trump has picked for key positions so far
President-elect Donald Trump has announced a flurry of picks for his incoming administration. Get full coverage of the Trump transition from The Washingon Times.
Trump dances onstage, takes post-election nation by storm
President-elect Trump dances onstage
